“Real World Data Survival Outcomes of First Line Immunotherapy With Pembrolizumab in High Expressers With Stage IV Non-Small Cell Lung Cancer”. 2026. Radiology and Oncology 60 (3): 450-58. https://radioloncol.com/index.php/ro/article/view/4876.